- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01932099
TranScatheter Aortic Valve RepLacement System US Feasibility Trial (SALUS)
The Direct Flow Medical TranScatheter Aortic Valve RepLacement System US Feasibility Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- UC Davis Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Washington University Hospital
-
-
New York
-
New York, New York, United States, 10032
- Columbia Univ. Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient has severe senile degenerative aortic valve stenosis determined by resting or dobutamine stress echocardiogram and Doppler, or simultaneous pressure recordings at cardiac catheterization defined as: mean gradient >40 mmHg or peak jet velocity >4.0 m/s and an aortic valve area ≤0.8 cm2 or aortic valve area index ≤0.5 cm2/m2.
- The patient has moderate to severe symptoms from aortic valve stenosis (NYHA Functional Class ≥III).
- The patient must have a predicted risk of operative mortality or serious irreversible morbidity of >50% at 30 days, or be deemed not suitable for surgery for other reasons. This conclusion shall be based on consensus of one cardiologist and two cardiac surgeons at the investigational site after careful consideration of the patient's STS risk score and co-morbidities, and after at least one of the surgeons participating in the decision has personally examined the patient.
- The patient been informed of the nature of the study, agrees to its provisions, is willing to comply with protocol-specified follow-up evaluations and has provided written informed consent, approved by the appropriate IRB.
Exclusion Criteria
- Left ventricular ejection fraction (LVEF) <20% determined by resting echocardiogram
- Patients with an acute MI within 30 days preceding the index procedure.
- Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the study procedure
- Patients with impaired renal function (estimated Glomerular Filtration Rate [eGFR] <20cc/min, calculated from serum creatinine by the Cockcroft-Gault formula)
- Patients with a platelet count of <50,000 cells/mm³ or a WBC < 1000 cells/mm³ within 7 days prior to index procedure.
- Patients with a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse transfusion.
- Patients who have received any organ transplant or are on a waiting list for any organ transplant.
- Patients with known other medical illness (e.g. carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease) or known history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation or is associated with a life expectancy of less than one year, or expectation that patient will not improve despite treatment of aortic stenosis.
- Patients with known hypersensitivity or contraindication to aspirin, heparin, clopidogrel/ticlopidine, and/or contrast sensitivity that cannot be adequately pre-medicated.
- Patients with a history of a stroke or transient ischemic attack (TIA) within the prior 6 months.
- Patients with an active gastrointestinal (GI) bleeding within the prior 6 months.
- Patients presenting with hemodynamic instability or cardiogenic shock defined by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
- Patients who have a planned treatment with any other investigational device or procedure during the study period, or who are currently participating in an investigational drug or another device trial
- Any planned surgical, percutaneous coronary or peripheral procedure to be performed prior to the 30 day follow-up from the TAVR procedure.
- Untreated clinically significant coronary artery disease requiring revascularization
- Trans-esophageal echocardiography (TEE) is contraindicated
- Active endocarditis or sepsis within 6 months prior to the study procedure
- Dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
- Congenital bicuspid or unicuspid valve determined by echocardiography
- Prior aortic or mitral valve surgery or pre-existing prosthetic heart valve in any position
- Native valve annulus diameter is <19mm or >26mm determined by the screening CT scan
- Extreme asymmetrical calcification of the native aortic valve determined by the screening CT scan
- Echocardiographic evidence of intra-cardiac mass, thrombus, vegetation, or spontaneous echo contrast in the left atrium
- >3+ aortic regurgitation, mitral regurgitation or tricuspid regurgitation
- Moderate to severe mitral stenosis
- Thoracic aortic aneurysm (TAA) or abdominal aortic aneurysm (AAA) >5.0 cm
- Presence of an endovascular stent graft for treatment of AAA or TAA 28 Hypertrophic obstructive cardiomyopathy
29. Patients with severe peripheral arterial disease that precludes sheath vascular access (e.g. luminal diameter less than 6.5 mm, severe obstructive calcification or severe tortuosity)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm feasibility study
Prospective, multi-center, single arm feasibility study.
Subjects will include patients with severe aortic valve stenosis who require replacement of their native aortic valve.
The intervention is transcatheter aortic valve replacement.
|
Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from all cause mortality/Device success
Time Frame: 6 months post procedure
|
Absence of procedural mortality AND correct positioning of a single prosthetic heart valve into the proper anatomic location AND Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient less than 20 mmHg or peak velocity less than 3m/s, AND no moderate or severe prosthetic valve regurgitation.
|
6 months post procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early Safety
Time Frame: 30 Days
|
Early Safety: as a composite of
|
30 Days
|
Clinical Efficacy
Time Frame: 6 months,and annually at 1 to 5 years
|
Clinical Efficacy will be evaluated as a composite of:
|
6 months,and annually at 1 to 5 years
|
Time-related Valve Safety
Time Frame: 30 days, 6 months and annually at 1 to 5 years
|
Time-related valve safety will be evaluated as a composite of:
|
30 days, 6 months and annually at 1 to 5 years
|
Clinical Endpoints
Time Frame: 30 days, 6 months and annually at 1 to 5 years.
|
Individual Endpoints
|
30 days, 6 months and annually at 1 to 5 years.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: E. Murat Tuzcu, MD, The Cleveland Clinic
- Principal Investigator: Patrick M McCarthy, MD, Northwestern Memorial Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IP 011
- G120160 (Other Identifier: Direct Flow Medical, Inc.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Sorin Group USA, Inc.TerminatedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
BC Centre for Improved Cardiovascular HealthEdwards LifesciencesUnknownTranscatheter Aortic Valve Implantation | Severe Aortic StenosisCanada
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Hospices Civils de LyonRecruiting
Clinical Trials on Transcatheter aortic valve replacement
-
IRCCS Policlinico S. DonatoRecruiting
-
Clinique PasteurUnknownBicuspid Aortic ValveFrance
-
Didier TCHETCHEAbbottNot yet recruitingBicuspid Aortic ValveFrance
-
Ole De BackerBoston Scientific Corporation; Abbott; Edwards Lifesciences; Symetis SAActive, not recruitingHeart Diseases | Cardiovascular Diseases | Aortic Valve Stenosis | Heart Valve Diseases | Ventricular Outflow ObstructionFinland, Norway, Sweden, Denmark, Iceland
-
University of PadovaFondazione GISE OnlusRecruiting
-
Xijing HospitalRecruitingAortic Valve RegurgitationChina
-
Xijing HospitalRecruiting
-
Xijing HospitalRecruitingAortic Valve Disease MixedChina
-
OptimapharmEdwards LifesciencesActive, not recruitingAortic Valve Stenosis | Heart Valve DiseasesUnited Kingdom, Italy, Germany, France, Austria, Switzerland, Finland, Czechia, Belgium, Netherlands, Cyprus, Ireland
-
Medical University of WarsawRecruitingAortic Valve Stenosis | Ventricular Outflow Obstruction, LeftPoland